J. Dixon

发表

PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

John M. S. Bartlett, Stefan Michiels, Christos Sotiriou, 2013, PloS one.

Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer.

Les Irwig, Petra Macaskill, Sarah J Lord, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combining and Sequencing Adjuvant Chemotherapy and Tamoxifen in Postmenopausal Women with Node-Positive Breast Cancer

J. Dixon, A. Leeper, 2010, Women's health.

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

M. Dowsett, S. Ebbs, J. Salter, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

M. Dowsett, R. A’Hern, E. Folkerd, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

M. Ellis, M. Dowsett, Y. Tao, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Src inhibitors in early breast cancer: a methodology, feasibility and variability study

P. Elvin, J. Dixon, C. Womack, 2009, Breast Cancer Research and Treatment.

An analysis of the content and morphology of human breast microcysts.

W. Miller, J. Dixon, W. Scott, 1985, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Classification of human breast cysts according to electrolyte and androgen conjugate composition.

A. Forrest, W. Miller, J. Dixon, 1983, Clinical oncology.

pH of human breast cyst fluids.

W. Miller, J. Dixon, W. Scott, 1984, Clinical oncology.

Reply to S. Pauwels et al.

M. Dowsett, E. Folkerd, J. Dixon, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

J. Carmichael, J. Dixon, J. Jaśkiewicz, 2013, Investigational New Drugs.

developed, we remain confident that results from our assay allow comparison of different drugs and patient groups and believe that any differences demonstrated are scientifically robust and valid.

M. Dowsett, E. Folkerd, J. Dixon, 2012 .

Uptake of dehydroepiandrosterone sulphate into human breast cyst fluids

R. Elton, W. Miller, J. Telford, 1997 .

Estrone and estradiol metabolism in vivo in human breast cysts☆ 1 1 ☆ A preliminary report was presented at the 45th Annual Meeting of the Society for Gynecologic Investigation, March 11–14, 1998, Atlanta, Georgia - abstract 185.

U. Raju, W. Miller, H. Bradlow, 2000, Steroids.

Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer

R. Greil, J. Baselga, H. Rugo, 2008 .

Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management.

R. Warren, S. Ciatto, L. Irwig, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

M. Dowsett, S. Ebbs, J. Blohmer, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

C. Sotiriou, S. Loi, M. Piccart, 2013, PloS one.

Edinburgh Research Explorer PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

C. Sotiriou, S. Loi, M. Piccart, 2018 .

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer

C. Perou, Xiaping He, J. Parker, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Selenium concentrations in feeds and effects of treating pregnant Holstein cows with selenium and vitamin E on blood selenium values and reproductive performance.

J. Dixon, R. H. Ingraham, L. Kappel, 1984, American journal of veterinary research.

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours

J. Cummings, J. Dixon, W. Miller, 2000, British Journal of Cancer.

Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in breast tumour tissues.

J. Cummings, J. Dixon, W. Miller, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

K. Gelmon, J. Baselga, J. Albanell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies

Baljit Singh, F. Baehner, D. Cameron, 2019, Advances in Therapy.

A randomized prospective trial comparing the value of intravenous and preincisional cefamandole in reducing postoperative sepsis after operations upon the gastrointestinal tract.

S. Duffy, U. Chetty, J. Dixon, 1984, Surgery, gynecology & obstetrics.

Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma.

J. Cummings, J. Dixon, W. Miller, 1996, Journal of chromatography. B, Biomedical applications.

Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer.

M. Dowsett, D. Cameron, E. Folkerd, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CCR-21-3189 3618..3629

C. Perou, Xiaping He, J. Parker, 2022 .

Aromatase inhibitors—Gene discovery

G. Hampton, W. Miller, J. Dixon, 2007, The Journal of Steroid Biochemistry and Molecular Biology.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

R. Greil, J. Baselga, H. Lane, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Local endocrine effects of aromatase inhibitors within the breast

J. Dixon, W. Miller, J. Dixon, 2001, The Journal of Steroid Biochemistry and Molecular Biology.

The pharmacology of letrozole

M. Dowsett, J. Dixon, B. Haynes, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies

J. Dixon, J. Dixon, 2006, Expert opinion on pharmacotherapy.

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

T. Sing, W. Miller, J. Dixon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Mitch Dowsett, Roger A'Hern, M. Dowsett, 2007, Journal of the National Cancer Institute.

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer

J. Dixon, A. Sims, L. Renshaw, 2010, Breast Cancer Research and Treatment.

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

Christopher M. Kirchhoff, Stuart James, S. Cawthorn, 2019, British Journal of Cancer.

Endocrine resistance in breast cancer – An overview and update

J. Tyson, R. Clarke, J. Dixon, 2015, Molecular and Cellular Endocrinology.

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.

M. Dowsett, D. Cameron, J. Dixon, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular changes in lobular breast cancers in response to endocrine therapy.

A. Turnbull, J. Dixon, C. Kay, 2014, Cancer research.

DCIS and aromatase inhibitors

J. Dixon, D. Faratian, Jeremy S. Thomas, 2007, The Journal of Steroid Biochemistry and Molecular Biology.

Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?

J. Dixon, J. Dixon, 2008, Breast.

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.

M. Dowsett, D. Cameron, R. A’Hern, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer

J. Dixon, J. Dixon, L. Renshaw, 2010, Breast Cancer Research and Treatment.